文献速递腹部儿科影像MR

钆塞酸二钠在儿童和青少年肝胆MRI中的安全性

Safety of Gadoxetate Disodium for Hepatobiliary MRI in Children and Adolescents.
PubMed 文献 · Radiology · 2024-01-01

回顾性分析2010年1月至2022年12月三家三级医院1079例儿童和青少年(≤18岁)的1629次MRI检查,比较肝胆特异性对比剂钆塞酸二钠与细胞外对比剂相关急性不良事件发生率,两者差异无统计学意义(1.3% vs 0.9%,OR 1.55,P=0.42),不良事件多为轻度,原文结论认为需进一步大规模儿童研究确认其安全性。

要点

  • 儿童和青少年使用钆塞酸二钠后急性不良事件发生率为1.3%(5/373次检查),细胞外对比剂为0.9%(11/1256次检查)。
  • 钆塞酸二钠组不良事件4例轻度、1例中度,细胞外对比剂组均为轻度。
  • 倾向评分匹配(OR 1.33,P=0.71)和逆概率治疗加权(OR 0.84,P=0.78)分析均显示两组无显著差异。

核心结论

  • 儿童和青少年使用钆塞酸二钠与细胞外对比剂相比,急性不良事件发生率无差异,原文认为需进一步大规模儿童研究确认其安全性。

研究设计与样本

  • 回顾性分析,纳入2010年1月至2022年12月三家三级医院≤18岁行肝胆特异性对比剂增强MRI的儿童和青少年,共1629次MRI检查(细胞外对比剂1256次、肝胆特异性对比剂373次),涉及1079例患者(平均年龄8.6岁±6.5,女566例);采用倾向评分匹配和基于九项协变量的逆概率治疗加权分析校正混杂因素。

诊断标准与关键数值

  • 不良事件严重程度按美国放射学会指南分为轻度、中度或重度;每次检查急性不良事件发生率:细胞外对比剂0.9%(11/1256)vs 肝胆特异性对比剂1.3%(5/373),OR 1.55(95%CI 0.54,4.46),P=0.42;倾向评分匹配OR 1.33(95%CI 0.30,5.96),P=0.71;逆概率治疗加权OR 0.84(95%CI 0.25,2.86),P=0.78。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文结论明确指出需进一步大规模儿童研究以确认其安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Despite a proven role in the characterization of liver lesions, use of the gadolinium-based contrast agent (GBCA) gadoxetate disodium at MRI is limited in children due to a lack of comparative safety data. Purpose To evaluate the safety of the GBCA gadoxetate disodium (a linear ionic hepatobiliary contrast agent [HBA]) in children and adolescents, compared with extracellular contrast agents (ECA). Materials and Methods A retrospective analysis was conducted in children and adolescents aged 18 years or younger who underwent HBA-enhanced MRI at one of three tertiary hospitals from January 2010 to December 2022. The incidence of GBCA-associated acute adverse events was compared between MRI examinations with a HBA and those with ECA. Severity was categorized according to American College of Radiology guidelines (mild, moderate, or severe). (a) Propensity score matching using multivariable logistic regression models and (b) inverse probability of treatment weighting analysis based on nine covariates (age, sex, asthma, allergic rhinitis, chronic urticaria or atopy, food allergy, drug allergy, premedication, and history of GBCA-associated adverse events) were used for confounder adjustment. Results A total of 1629 MRI examinations (ECA, n = 1256; HBA, n = 373) in 1079 patients were included (mean age, 8.6 years ± 6.5; 566 girls). The per-examination incidence of GBCA-associated acute adverse events showed no evidence of a difference, with rates of 0.9% (11 of 1256 examinations) for ECA and 1.3% (five of 373 examinations) for HBA (odds ratio [OR], 1.55 [95% CI: 0.54, 4.46]; P = .42). Acute adverse events were all mild with ECA, whereas with HBA, they were mild for four patients and moderate for one patient. There was no evidence of a difference in the incidence of acute adverse events, even in propensity score matching (OR, 1.33 [95% CI: 0.30, 5.96]; P = .71) and inverse probability of treatment weighting analysis (OR, 0.84 [95% CI: 0.25, 2.86]; P = .78). Conclusion Gadoxetate disodium showed no difference in acute adverse events compared with ECA in children and adolescents, with further large-scale pediatric studies required to confirm its safety. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Otero in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kim PH, Hwang JY, Choi YH, et al. Safety of Gadoxetate Disodium for Hepatobiliary MRI in Children and Adolescents. Radiology. 2024. PMID: 38860893. doi:10.1148/radiol.232462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。